^
Association details:
| Biomarker: | EML4-ALK fusion + ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P84.02 - A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group
Published date:
01/12/2021
Excerpt:
Patients with ALK-rearranged tumors...with EML4-ALK-positive non-small-cell lung cancer (NSCLC) refractory to alectinib...received single agent crizotinib monotherapy...The overall response rate was 33.3% (3 of 9; 90% confidence interval: 9.8–65.5 and 95% confidence interval [CI]: 7.5-70.1)...One-year-overall survival rate and median survival time were 66.7% and 24.1 months, respectively.
